In Vitro Postantibiotic Effects of Rifapentine, Isoniazid, and Moxifloxacin against Mycobacterium tuberculosis-Reference-Cited by-同舟云学术

In Vitro Postantibiotic Effects of Rifapentine, Isoniazid, and Moxifloxacin against Mycobacterium tuberculosis

Published:2004-01 Issue:1 Volume:48 Page:340-343
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Chan Chiu-Yeung¹,Au-Yeang Carrie¹,Yew Wing-Wai²,Leung Chi-Chiu³,Cheng Augustine F. B.¹

Affiliation:

1. Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories

2. Tuberculosis and Chest Unit, Grantham Hospital, Aberdeen

3. Tuberculosis and Chest Service, Department of Health, Hong Kong

Abstract

ABSTRACT Postantibiotic effects (PAEs) of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis ATCC 27294 were studied using a radiometric culture system. Rifapentine at 20 mg/liter gave the longest PAE (104 h) among the drugs used alone. The combinations of rifapentine plus isoniazid, rifapentine plus moxifloxacin, and isoniazid plus moxifloxacin gave PAEs of 136.5, 59.0, and 8.3 h, respectively.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.48.1.340-343.2004

Reference24 articles.

1. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

2. Bock, N. N., T. R. Sterling, C. D. Hamilton, C. Pachucki, Y. C. Wang, D. S. Conwell, A. Mosher, M. Samuels, A. Vernon, et al. 2002. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am. J. Resp. Crit. Care Med.165:1526-1530.

3. Bundtzen, R. W., A. U. Gerber, D. L. Cohn, and W. A. Craig. 1981. Post-antibiotic suppression of bacterial growth. Rev. Infect. Dis.3:28-37.

4. Burkhardt, O., K. Borner, H. Stass, G. Beyer, M. Allewelt, C. E. Nord, and H. Lode. 2002. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand. J. Infect. Dis.34:898-903.

5. Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin Antibacterials

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Vitro and In Vivo Activity of Gepotidacin against Drug-Resistant Mycobacterial Infections;Antimicrobial Agents and Chemotherapy;2022-12-20

2. In vitro and in vivo activity of Gepotidacin against drug-resistant mycobacterial infections;2022-08-20

3. Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis;Antimicrobial Agents and Chemotherapy;2021-10-18

4. In Vitro Profiling of Antitubercular Compounds by Rapid, Efficient, and Nondestructive Assays Using Autoluminescent Mycobacterium tuberculosis;Antimicrobial Agents and Chemotherapy;2021-07-16

5. Modern Drug Discovery and Development for TB: The India Narrative;Drug Discovery and Drug Development;2021